Please provide your email address to receive an email when new articles are posted on . The FDA approved a third-generation PCSK9 inhibitor to reduce cholesterol in certain high-risk patients. The ...

What began as a search for hormone-processing enzymes ultimately transformed the treatment of high cholesterol.

The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...

ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL cholesterol levels with just a single, quick, once-monthly dose, the phase III LIBerate-HR trial showed. Lerodalcibep reduced LDL cholesterol by ...

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.

Over the past several days, two major developments have emerged in the world of cholesterol-lowering therapies—specifically concerning the heavy-hitters known as PCSK9 inhibitors. In this letter, I’d ...

Enlicitide demonstrated statistically significant and clinically meaningful reductions in LDL-C in both Phase 3 CORALreef HeFH and CORALreef AddOn trials Enlicitide, a novel macrocyclic peptide, has ...

AstraZeneca’s small molecule lowered levels of “bad” cholesterol by more than half in patients who had never received treatment for their condition, according to results from an early-stage trial. The ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment ...

A concise, high-yield guide to cholesterol-lowering therapies—statins, Zetia, PCSK9 inhibitors, bempedoic acid, berberine, ...

CORALreef Lipids randomized 2,909 adults (2:1) to enlicitide 20 mg daily or placebo across 168 sites, using stratification by renal function, baseline statin use, and region. LDL-C at week 24 ...